Harmony Biosciences (HRMY) · page 160 of 366
The slide highlights the FDA's 'wait-and-see' posture and specific concerns about seizures as a safety signal for the drug pitolisant.
Research note · preempt_rebuttal · preempt_rebuttal · dense density
Slide locked Sign in to view
Slide schematic 7/7
callout 1/1 paragraph 5/5 source-note 1/1
Components 7
primary paragraph paragraph paragraph paragraph paragraph source-note
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.